<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Rare Disease</title>
    <link rel="stylesheet" href="/styles.css">
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link href="https://fonts.googleapis.com/css2?family=Bebas+Neue&family=Roboto:wght@400;500&display=swap" rel="stylesheet">

    </head>
    <body>
        <nav id="navbarWhole">
            <div id="NavbarTitleDiv">
            <h1 id="navbarTitle">THE FACT CHECKER</h1>
            </div>
            <div>
            <ul id="navbarList">
                <li><a href="/index.html">Home</a></li>
                <li><a href="/aboutUs.html">About Us</a></li>
                <li><a href="/contactUs.html">Contact us</a></li>
                </ul>
            </div>
        </nav>
        <div id="newsBody">
            <div id="newsTitleDiv"> 
        <h1>Rare Diseases Gain New Attention and Hope As Gene Therapy Advances Accelerate</h1>
        </div>
        <div id="newsInternalBody">
            <img id ="newsImage"src="/images/rareDisease.jpg"/>
            <div id="newsTextBlock">
            <p class="newsText">Long overlooked rare diseases are garnering fresh attention and funding as breakthrough gene therapies show new promise for treatments. Advances in genetic medicine have led to a wave of clinical trials targeting thousands of lesser known conditions.</p>
            <p class="newsText">Pharmaceutical companies are increasingly drawn to develop life-changing gene treatments for these niche disorders historically ignored by research. Gene silencing, editing and replacement techniques provide new ways to correct root mutations causing rare illnesses in one treatment.</p>
            <p class="newsText">While costs and access remain hurdles, disease advocacy groups say the progress provides hope to neglected patient populations. Gene therapy momentum could help unlock diagnoses and personalized treatments for rare disease families long resigned to manage little-understood conditions. Major regulatory approvals in the coming years may mean turning the tide for overlooked disorders to enter the biotech mainstream.</p>
        </div>
        </div>
        <div id="newsBarBodyRed">
            <h1 id="newsBarTitle">THE FACT CHECKER</h1>
            <h1 id="newsBarScore">14%</h1>
            <h3>Source: Reuters</h3>
           </div>
        </div>
    </body>
</html>